Loading…
Kyverna Therapeutics, Inc. is projected to rise to $9.74 by 2027, a +13% move from its current price of $8.59. KYTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $8.22 | $8.59 | $8.98 | +0.03% |
| May 30 | $8.07 | $8.59 | $9.15 | +0.05% |
| May 31 | $7.96 | $8.60 | $9.28 | +0.08% |
| Jun 1 | $7.87 | $8.60 | $9.40 | +0.11% |
| Jun 2 | $7.79 | $8.60 | $9.50 | +0.13% |
| Jun 3 | $7.72 | $8.60 | $9.59 | +0.16% |
| Jun 4 | $7.65 | $8.61 | $9.68 | +0.19% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.65 | $8.61 | $9.68 | +0.19% |
| Week 2 | $7.30 | $8.62 | $10.18 | +0.37% |
| Week 3 | $7.05 | $8.64 | $10.59 | +0.56% |
| Week 4 | $6.84 | $8.65 | $10.95 | +0.75% |
| Week 5 | $6.67 | $8.67 | $11.28 | +0.94% |
| Week 6 | $6.51 | $8.69 | $11.58 | +1.13% |
| Week 7 | $6.38 | $8.70 | $11.88 | +1.32% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Kyverna Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. Its lead product KYV-101 is an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
It is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product.
The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Kyverna Therapeutics, Inc. trades under the symbol KYTX. The current price is $8.67 and the market capitalization is $527.09M. The company is ranked 3004 in market capitalization. The forecast suggests a long-run bullish trajectory with notable upside by 2030 and 2050, though near-term results are more subdued.
A major floor 23.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.2% away) — a key level to hold.
The nearest ceiling, 31.0% above — a clean break opens room to run.
A major ceiling 42.8% above — clearing it would confirm fresh momentum.
Key KYTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KYTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.67 | Sell | $8.72 | Sell |
| MA 10 | $9.16 | Sell | $8.95 | Sell |
| MA 20 | $9.23 | Sell | $9.13 | Sell |
| MA 50 | $9.04 | Sell | $9.04 | Sell |
| MA 100 | $8.71 | Sell | $8.61 | Sell |
| MA 200 | $7.50 | Buy | $7.77 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.76 | Neutral |
| Stoch RSI (14) | 5.46 | Buy |
| CCI (20) | -72.38 | Neutral |
| Williams %R (14) | -97.77 | Info |
| MACD (12,26,9) | -0.15 | Sell |
| ROC (12) | -8.13 | Sell |
| Bollinger %B (20,2) | 0.28 | Neutral |
| Stochastic %K (14) | 2.23 | Buy |
| TRIX (15) | 0.04 | Buy |
| Awesome (5,34) | -0.68 | Sell |
| Ultimate (7,14,28) | 33.27 | Neutral |
| Momentum (10) | -1.64 | Sell |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 8.51 | Buy |
| ADX (14) | 12.47 | Neutral |
| ATR (14) | 0.34 | Info |
The near-term technical picture is neutral. The RSI14 is 40, with the stock trading around key moving averages. The SMA50 is $9.06 and the SMA200 is $7.45, placing the current price near the midpoint of these indicators.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.26 | $8.59 | $10.94 | 0% | Neutral | |
| $7.26 | $9.74 | $14.08 | +13% | Neutral | |
| $6.26 | $8.82 | $13.44 | +3% | Neutral | |
| $6.11 | $8.96 | $14.24 | +4% | Neutral | |
| $8.08 | $12.28 | $20.21 | +43% | Bullish | |
| $9.38 | $14.75 | $25.01 | +72% | Bullish | |
| $10.07 | $16.36 | $28.48 | +90% | Bullish | |
| $9.79 | $16.40 | $29.25 | +91% | Bullish | |
| $9.08 | $15.66 | $28.56 | +82% | Bullish | |
| $9.71 | $17.24 | $32.08 | +101% | Bullish | |
| $13.23 | $26.91 | $54.48 | +213% | Bullish | |
| $26.20 | $58.23 | $132.89 | +578% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $7.26 | $8.59 | $10.21 | +0.00% |
| June 2026 | $7.54 | $8.98 | $11.03 | +4.49% |
| July 2026 | $7.29 | $8.80 | $11.05 | -1.93% |
| August 2026 | $6.84 | $8.35 | $10.65 | -5.16% |
| September 2026 | $6.83 | $8.41 | $10.87 | +0.74% |
| October 2026 | $6.89 | $8.56 | $11.19 | +1.76% |
| November 2026 | $6.60 | $8.26 | $10.92 | -3.46% |
| December 2026 | $6.50 | $8.20 | $10.94 | -0.79% |
Click any year to see its month-by-month KYTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect KYTX to range from $7.26 to $10.94 through 2026. The $8.59 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The KYTX price prediction for 2027 points to an average of $9.74 (low $7.26, high $14.08) — a potential gain of +13% on today's $8.59. Price action looks broadly range-bound.
In 2028, KYTX is projected to trade between $6.26 and $13.44, averaging $8.82 — a potential gain of +3% from today's $8.59. That is -9% versus the projected 2027 average. A consolidation phase looks the most probable path here.
Kyverna Therapeutics, Inc.'s 2029 outlook centres on $8.96, within a $6.11 to $14.24 range. That is up +2% on the projected 2028 average. That marks a +4% change versus current levels. Price action looks broadly range-bound.
By 2030, KYTX could reach as high as $20.21, with a base case around $12.28 and support toward $8.08 — roughly +43% from $8.59. Buyers look set to stay in control over this stretch.
Expect KYTX to range from $9.38 to $25.01 through 2031. The $14.75 average target implies a +72% move from current prices. That is up +20% on the projected 2030 average. Momentum favours further upside here.
The KYTX price prediction for 2032 points to an average of $16.36 (low $10.07, high $28.48) — a potential gain of +90% on today's $8.59. Buyers look set to stay in control over this stretch.
In 2033, KYTX is projected to trade between $9.79 and $29.25, averaging $16.40 — a potential gain of +91% from today's $8.59. That is up 0% on the projected 2032 average. Momentum favours further upside here.
Kyverna Therapeutics, Inc.'s 2034 outlook centres on $15.66, within a $9.08 to $28.56 range. That is -4% versus the projected 2033 average. That marks a +82% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, KYTX could reach as high as $32.08, with a base case around $17.24 and support toward $9.71 — roughly +101% from $8.59. Momentum favours further upside here.
Expect KYTX to range from $13.23 to $54.48 through 2040. The $26.91 average target implies a +213% move from current prices. That is up +56% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The KYTX price prediction for 2050 points to an average of $58.23 (low $26.20, high $132.89) — a potential gain of +578% on today's $8.59. Momentum favours further upside here.
Investing $1,000 in KYTX today (≈ 116.414435 KYTX) could be worth
$6,778.45
+$5,778.45 (+578%) by 2050 · US Dollar
Based on the average projected KYTX price of $58.23 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KYTXwould be worth at today's price.
$1,000 invested in KYTX on May 27, 2025 (≈ 387.596911 KYTX) would be worth
$3,329.46
+$2,329.46 (+232.9%) today · 3.33× · US Dollar
Based on a KYTX entry price of $2.58 vs. today's $8.59.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.57 | $1,002.33 | +0.2% |
| 1 month ago | $8.99 | $955.51 | -4.4% |
| 3 months ago | $8.12 | $1,057.88 | +5.8% |
| 6 months ago | $7.67 | $1,119.95 | +12.0% |
| 1 year ago | $2.58 | $3,329.46 | +232.9% |
| All time (2.3y) ago | $30.1 | $285.38 | -71.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KYTX forecast.
Our base-case forecast reaches $17.00 around 2035.
Implied market cap at $17.00: $1.03B
The multi-year forecast shows a path from a neutral near-term into a bullish longer-term outlook. In 2026 the avg price is $8.67 with a min of $7.26 and a max of $11.15 and 0% ROI. By 2030 the avg rises to $12.42 with a max of $20.82 and a 43.2% ROI, signaling a bullish shift.
The forecast continues to show gains through 2031–2035, with 2031 avg $14.74 (ROI 70%), 2032 avg $16.47 (ROI 90%), 2033 avg $16.47 (ROI 89.9%), 2034 avg $15.39 (ROI 77.5%), and 2035 avg $17.23 (ROI 98.8%) as drivers of upside. By 2040 the avg is $26.43 (ROI 204.8%), and by 2050 the avg is $58.85 (ROI 578.8%), with a max of $135.36. These figures imply a sustained bullish trajectory, though all values are estimates and not guarantees.
The forecast consistently labels sentiment as BULLISH from 2030 onward, after a period of NEUTRAL readings in 2026–2029.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $12.42 with a max of $20.82 and a min of $8.00, and a 43.2% ROI with a bullish sentiment.
Near-term readings are NEUTRAL (2026–2029) with mixed results, but the forecast shows a bullish trajectory from 2030 onward, with substantial upside by 2050. Remember these are estimates, not guarantees.
The 2050 max is $135.36 and the 2050 avg is $58.85, so reaching around $60 is possible in the max scenario but the average by 2050 is below $60. Forecasts are not guarantees.
Current price is $8.67 and market cap is $527.09M.
RSI14 is 40; SMA50 is $9.06; SMA200 is $7.45. The 30-day range is $6.35 to $11.83, with support at $8.40 and resistance at $11.25.
Kyverna Therapeutics, Inc. Community Discussion
0Share your Kyverna Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.